ibrutinib and fcr in cll irrespective of ighv mutation status
Published 2 years ago • 278 plays • Length 1:44Download video MP4
Download video MP3
Similar videos
-
2:32
ifcg for first-line treatment of ighv-mutated cll
-
1:05
final analysis of the alpine trial: zanubrutinib vs ibrutinib in r/r cll
-
2:39
the safety and efficacy of ibrutinib for the treatment of cll
-
3:12
ibrutinib and rituximab shows superior pfs vs. fcr in cll
-
1:23
interim analysis of the flair study: efficacy of ibrutinib plus venetoclax in ighv unmutated cll
-
2:58
results of a phase ib study of ibrutinib obinutuzumab in r/r cll
-
1:50
the impact of ighv mutational status in treatment decisions in cll
-
2:07
efficacy of ibrutinib in the treatment of cll patients with del(17p) and tp53 mutation
-
5:29
long term follow-up with ibrutinib venetoclax to treat chronic lymphocytic leukemia
-
25:09
cll: long-term updates on ibrutinib and idelalisib
-
2:25
results from a phase i/ii trial of pirtobrutinib and lv20.19 for patients with r/r lymphomas
-
1:37
causes & management of ibrutinib discontinuation in cll
-
1:42
ibrutinib and fcr chemoimmunotherapy: improving complete remission in cll patients?
-
2:55
clinical outcomes of patients with cll receiving long-term ibrutinib in the resonate-2 study
-
2:38
ibrutinib treatment for cll does not increase the incidence of richter’s transformation
-
3:46
the characteristics and mode of action of ibrutinib for cll
-
1:56
ibrutinib plus venetoclax for first-line treatment of cll: 4-year follow-up data
-
2:06
the role of ibrutinib in the frontline treatment of young patients with cll
-
1:28
frontline ibrutinib-fcr for younger cll patients: phase ii results
-
1:35
ifcg: a promising new regimen for treating ighv-mutated cll
-
2:00
ibrutinib: use in small cll subgroups only?
-
4:29
first-line ibrutinib vs chemoimmunotherapy in cll: a real-world data analysis